Express Scripts staking out million-dollar gene therapies - (Yahoo!Finance via NewsPoints Desk)

  • Express Scripts is currently in negotiations with BioMarin Pharmaceutical, bluebird bio and Spark Therapeutics to become their exclusive distributors of their new haemophilia therapies, as reported Yahoo!Finance Wednesday.

  • Chief medical officer Steve Miller said the drugs should become available in 2019 and 2020.

  • BioMarin, Spark and bluebird confirmed that they are speaking to pharmacy benefit managers, health plans and government agencies regarding pricing models for future treatments.

  • "Even if they charge $1 million, that's a great deal," Miller commented, adding "so there are going to be some gene therapies where it is very clear that everyone who has that disease should get it."

  • Express Scripts previously inked deals to distribute Spark's Luxturna and Biogen's Spinraza, while it also helps manage Novartis' Kymriah.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>    

To read more NewsPoints articles, click here.